JPRN-C000000165未知2 期
Study of Docetaxle and trastuzumab as preoperative chemotherapy for advanced-stage breast cancer with HER2 over expression - Study of Docetaxle and trastuzumab as preoperative chemotherapy for advanced-stage breast cancer with HER2 over expression
Toukai Breast Cancer Clinical Reserch Group0 个研究点目标入组 40 人开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Drug allergy 2)Distant metastasis 3)Bilateral breast cancer 4)male 5)Double cancer 6)Uncontrollable complication 7)Heart disease 8) LVEF<50% by echocardiogram 9)Cardiac performance class II, III and IV by New York Heart Association Functional Classification 10)Sever infection 11)Motor paralysis or neuropathy 12)Pleural or subpericardial effusion 13)Pregnancy 14)Edema with grade G2 or more 15)Interstitial pneumonia or pulmonary fibrosis 16)Hypersensitivity for polysorubate 17) Positive HBs antigen 18)Psychological disease 19)Others
研究者
相似试验
已完成
不适用
Phase II study of preoperative Docetaxel, cisplatin and S-1 in patients with clinically respectable type 4 , large type 3 and with extensive lymph node metastasis gastric cancerGastric cancerJPRN-UMIN000003052Department of Surgery, Yokohama City University30
已完成
1 期
Phase I study of preoperative Docetaxel, Cisplatin and S-1 for patients with advanced gastric cancerPatients with unresectable gastric cancer due to limited invasion and/or metastasis.JPRN-UMIN000001025Dept. of Gastroenterologic Surgery, Kanazawa University Hospital24
已完成
2 期
preoperative combined chemothrapy with docetaxel, cisplatin and S-1 in local advanced gastric cancer; multicentric phase II studylocal advanced gastric cancer (excluding T3-4, bulky N2 &N3 and giant type3 &type 4)JPRN-UMIN000002081Society for the study of DCS therapy55
已完成
2 期
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerNCT00004888National Cancer Institute (NCI)84
已完成
2 期
Phase 2 study of trastuzumab and docetaxel therapy for HER2-positive recurrent/metastatic salivary gland carcinomaHER2-positive salivary gland carcinomaJPRN-UMIN000018165Hokkaido University Hospital16